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Acute Charcot Foot
C
harcot neuro-osteoarthropathy
(CNO) is a devastating complica-
tion of diabetes characterized by
increased local bone resorption medi-
ated by osteoclasts. Often CNO leads to
multiple fractures and joint destruction
resulting in severe deformity of the foot.
Osteoclasts are multinucleated cells that
have a common precursor with monocytes/
macrophages(1).Previously,wereported
that the number of osteoclasts generated
in vitro from circulating cells was higher
in acute CNO patients compared with di-
abetic control subjects and was partially
independent from receptor activator for
NF-kB (RANK)-RANK ligand (RANKL),
the main osteoclastogenic mediator (2).
One hypothesis could be that the number
of circulating osteoclast precursors is in-
creased in CNO. Among all monocytes
subpopulations, CD14-positive cells are
the most potent to transform into bone-
resorbing osteoclasts (3).
We studied 11 diabetic patients with
recent onset of acute CNO, 10 diabetic
patientswithnoprevioushistoryofCNO,
and 6 healthy control participants. All
patients were matched for age, sex, and
duration of diabetes. Mean serum creati-
nine and vibration perception threshold
on the apex of the hallux were not
different between CNO and diabetic pa-
tients. Patients with bone diseases (oste-
oporosis, rheumatoid arthritis, Paget’s
disease) were excluded from this study.
This study had research ethics committee
approval and was carried out in accor-
dance with the Declaration of Helsinki.
Peripheral blood mononuclear cells were
isolatedandthenumberofCD14-positive
monocytes was determined by ﬂow cy-
tometry. Serum concentration of tumor
necrosis factor (TNF)-a, interleukin-1b,
and LIGHT were determined by ELISA.
Data were compared using Mann-Whitney
U test and linear regression analysis.
The percentage of CD14-positive cells
in CNO was signiﬁcantly increased by
1.7–fold (9.06 6 3.64 vs. 4.98 6 2.68%,
P 5 0.012) and 2.1–fold (9.06 6 3.64 vs.
4.0 6 2.0%, P 5 0.016) compared with
diabetic patients and healthy participants,
respectively. Compared with diabetic pa-
tients and healthy participants, in CNO
serum levels of TNF-a were signiﬁcantly
increased by 1.7–fold (4.3 6 0.9 vs.
2.43 6 0.3 pg/mL, P 5 0.014) and 2.2–
fold (4.3 6 0.9 vs. 1.93 6 0.8 pg/mL, P 5
0.009). In CNO, a strong correlation was
encountered between the percentage of
CD14-positive cells and the serum levels
of TNF-a (R 5 0.78). LIGHT was only
detectable in the serum of six acute
CNO patients but was increased signiﬁ-
cantly compared with diabetic patients
(P 5 0.018) and healthy participants
(P 5 0.018). A poor correlation (R 5
0.02) between the percentage of CD14-
positive cells and the serum levels of
LIGHT was observed in CNO. On the
other hand, although interleukin-1b was
detectable in eight acute CNO patients,
sixdiabeticpatients,andtwohealthyvol-
unteers, these levels were not signiﬁ-
cantlydifferentbetweenthethreegroups
of patients, and no correlation was ob-
served between the number of CD14-
positive cells and serum levels of this
mediator.
Our results suggest that the exces-
sive bone resorption in CNO could poten-
tially be linked to increases in circulating
osteoclast precursors and serum levels of
TNF-a. With the recent development of
anti-TNF biological therapies and based
on our ﬁndings, it is plausible to suggest
the use of this therapeutic approach for
controlling CNO.
GUILLAUME MABILLEAU, PHD
1
N. PETROVA, MD
2
M.E. EDMONDS, MD
2
A. SABOKBAR, PHD
1
From the
1Institute of Musculoskeletal Sciences,
Nufﬁeld Department of Orthopaedics, Rheuma-
tology and Musculoskeletal Sciences, University
of Oxford, Oxford, U.K.; and the
2Diabetic Foot
Clinic, King’s College Hospital, London, U.K.
Corresponding author: Guillaume Mabilleau,
guillaume.mabilleau@univ-angers.fr.
G.M. is currently afﬁliated with INSERM, U922-
LHEA, University of Angers, Angers, France.
DOI: 10.2337/dc10-1695
© 2011 by the American Diabetes Association.
Readers may use this article as long as the work is
properly cited, the use is educational and not for
proﬁt, and the work is not altered. See http://
creativecommons.org/licenses/by-nc-nd/3.0/ for
details.
Acknowledgments—G.M. and N.L. were
supported by Diabetes UK grants (09/
0003836 and 05/0003025, respectively).
N.L. was also the recipient of a European
Foundation for the Study of Diabetes/Astra-
Zeneca Clinicaltravelfellowship. The Nufﬁeld
Department of Orthopaedics, Rheumatology
and Musculoskeletal Sciences, University of
Oxford received ﬁnancial support from Na-
tional Institute for Health Research Biochem-
icalResearchUnit.Nootherpotentialconﬂicts
of interest relevant to this article were reported.
G.M. researched data, contributed to dis-
cussion, wrote the manuscript, and reviewed
and edited manuscript. N.P. researched data,
contributed to discussion, and reviewed and
edited the manuscript. M.E.E. contributed to
discussion, wrote the manuscript, and re-
viewed and edited the manuscript. A.S. re-
viewed and edited the manuscript.
cccccccccccccccccccccccc
References
1. Udagawa N, Takahashi N, Akatsu T, et al.
Origin of osteoclasts: mature monocytes
and macrophages are capable of differenti-
ating into osteoclasts under a suitable
microenvironment prepared by bone
marrow-derived stromal cells. Proc Natl
Acad Sci USA 1990;87:7260–7264
2. Mabilleau G, Petrova NL, Edmonds ME,
Sabokbar A. Increased osteoclastic activity
in acute Charcot’s osteoarthropathy: the
role of receptor activator of nuclear factor-
kappaB ligand. Diabetologia 2008;51:
1035–1040
3 .H u s h e e mM ,N y m a nJ K ,V ä ä r ä n i e m iJ ,
Vaananen HK, Hentunen TA. Character-
ization of circulating human osteoclast
progenitors: development of in vitro re-
sorption assay. Calcif Tissue Int 2005;
76:222–230
care.diabetesjournals.org DIABETES CARE, VOLUME 34, MARCH 2011 e33
ONLINE LETTERS